Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
August 18, 2014 16:05 ET
|
Prothena Corporation plc
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Reports Second Quarter 2014 Financial Results and R&D Progress
August 04, 2014 16:05 ET
|
Prothena Corporation plc
Completion of successful public equity offering netting $102.5 million and net cash provided by operating activities of $6.2 million in second quarter 2014 contributed to strengthen cash position...
Initiation of Multiple Ascending Dose Phase 1 Study of PRX002 in Patients With Parkinson's Disease
July 31, 2014 16:05 ET
|
Prothena Corporation plc
First Patient with Parkinson's Disease Successfully Dosed in Second Phase 1 Study
Trial Designed to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity
Multiple Biomarkers...
Prothena Announces Pricing of Public Offering of 4,750,000 Ordinary Shares
June 25, 2014 08:00 ET
|
Prothena Corporation plc
DUBLIN, Ireland, June 25, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Announces Proposed Offering of Ordinary Shares
June 23, 2014 16:17 ET
|
Prothena Corporation plc
DUBLIN, Ireland, June 23, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena to Present at the Jefferies 2014 Global Healthcare Conference in New York
May 27, 2014 16:05 ET
|
Prothena Corporation plc
DUBLIN, Ireland, May 27, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena Reports First Quarter 2014 Financial Results and Provides R&D Updates
May 05, 2014 16:05 ET
|
Prothena Corporation plc
Encouraging cardiac biomarker responses from ongoing Phase 1 of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction presented at ISA
Additional Phase 1 data updates of...
Prothena to Host Webcast and Conference Call to Discuss Interim Phase 1 Data of Ongoing NEOD001 Study in Patients With AL Amyloidosis on May 2
May 01, 2014 16:05 ET
|
Prothena Corporation plc
DUBLIN, May 1, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies...
Prothena Announces Appointment of Chief Legal Officer
April 30, 2014 16:30 ET
|
Prothena Corporation plc
DUBLIN, Ireland, April 30, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel...
Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
April 23, 2014 11:44 ET
|
Prothena Corporation plc
NEOD001 appears generally safe, well-tolerated, has acceptable pharmacokinetic properties and no immunogenicity at studied dose levels
No dose limiting toxicities have been observed
Eight...